Drug Profile
Tozasertib
Alternative Names: MK-0457; VX-680Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Vertex Pharmaceuticals
- Developer Merck & Co
- Class Antineoplastics; Piperazines; Small molecules
- Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors; Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Haematological malignancies; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 03 Jun 2008 Preclinical pharmacodynamics data of combination of tozasertib with vorinostat in Chronic myeloid leukaemia presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
- 20 Nov 2007 Merck & Co suspends patient enrollment in clinical trials of tozasertib until full analysis of clinical data can be conducted
- 04 Jan 2007 Data presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH-2006) added to the adverse events and Cancer therapeutic trials and pharmacodynamics sections